Global Search

Hide Filters

Showing 2039 results

Clinical Trials / Mar 06, 2026

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Clinical Trials / Mar 30, 2026

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Clinical Trials / Jan 30, 2026

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Press release / Jun 28, 2018

Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine

Results from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
Press release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified…
Press release / Mar 26, 2020

Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

Collaboration to address product development and scale up challenges posed by current pandemic Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an…
Press release / Feb 24, 2020

Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)

Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
Press release / Apr 30, 2019

New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions

Novartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple…
Press release / Sep 07, 2020

Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings

High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair…
Press release / May 19, 2020

AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

Zolgensma® (onasemnogene abeparvovec) is conditionally approved in Europe for the treatment of patients with spinal muscular atrophy (SMA) and a clinical diagnosis of SMA Type 1; or SMA patients with…